
Merete L Hetland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9206478/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
2	Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis and Rheumatism, 2010, 62, 22-32.	6.7	459
3	MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Annals of the Rheumatic Diseases, 2009, 68, 384-390.	0.9	335
4	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 491-496.	0.9	209
5	Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry. Arthritis and Rheumatism, 2011, 63, 382-390.	6.7	204
6	A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Annals of the Rheumatic Diseases, 2017, 76, 1426-1431.	0.9	204
7	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, 2011, 70, 1575-1580.	0.9	188
8	Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases, 2010, 69, 2002-2008.	0.9	185
9	QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Annals of the Rheumatic Diseases, 2007, 66, 1491-1496.	0.9	172
10	Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Annals of the Rheumatic Diseases, 2010, 69, 1789-1795.	0.9	168
11	Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Annals of the Rheumatic Diseases, 2009, 68, 1666-1672.	0.9	163
12	Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis and Rheumatism, 2006, 54, 1401-1409.	6.7	160
13	Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry. Arthritis and Rheumatism, 2013, 65, 1213-1223.	6.7	159
14	Remission and rheumatoid arthritis: Data on patients receiving usual care in twentyâ€four countries. Arthritis and Rheumatism, 2008, 58, 2642-2651.	6.7	156
15	Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry. Annals of the Rheumatic Diseases, 2013, 72, 79-82.	0.9	150
16	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.9	150
17	Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1528-37.	2.0	148
18	No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Annals of the Rheumatic Diseases, 2011, 70, 252-258.	0.9	140

#	Article	IF	CITATIONS
19	Low bone mass and high bone turnover in male long distance runners Journal of Clinical Endocrinology and Metabolism, 1993, 77, 770-775.	3.6	132
20	Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases, 2015, 74, e12-e12.	0.9	132
21	Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflammatory Bowel Diseases, 2011, 17, 2340-2349.	1.9	125
22	Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases, 2013, 72, 1149-1155.	0.9	123
23	To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Annals of the Rheumatic Diseases, 2019, 78, 192-200.	0.9	123
24	The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clinical Epidemiology, 2016, Volume 8, 737-742.	3.0	119
25	DANBIOpowerful research database and electronic patient record. Rheumatology, 2011, 50, 69-77.	1.9	113
26	Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases, 2011, 70, 1216-1222.	0.9	112
27	Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Annals of the Rheumatic Diseases. 2014. 73. 654-661.	0.9	108
28	Plasma Adiponectin in Patients with Active, Early, and Chronic Rheumatoid Arthritis Who Are Steroid- and Disease-Modifying Antirheumatic Drug-Naive Compared with Patients with Osteoarthritis and Controls. Journal of Rheumatology, 2009, 36, 1885-1891.	2.0	106
29	Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Panâ€European Registry Analysis. Arthritis and Rheumatology, 2016, 68, 1346-1352.	5.6	102
30	Synovitis and Osteitis Are Very Frequent in Rheumatoid Arthritis Clinical Remission: Results from an MRI Study of 294 Patients in Clinical Remission or Low Disease Activity State. Journal of Rheumatology, 2011, 38, 2039-2044.	2.0	101
31	Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Annals of the Rheumatic Diseases, 2017, 76, 105-111.	0.9	97
32	Low bone mass and high bone turnover in male long distance runners. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 770-775.	3.6	96
33	Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. PLoS ONE, 2017, 12, e0180014.	2.5	95
34	Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy x-ray absorptiometry. Journal of Bone and Mineral Research, 1994, 9, 1975-1980.	2.8	94
35	Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 2014-2020.	2.0	94
36	Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Annals of the Rheumatic Diseases, 2008, 67, 815-822.	0.9	93

Merete L Hetland

#	Article	IF	CITATIONS
37	Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Annals of the Rheumatic Diseases, 2007, 66, 1184-1189.	0.9	90
38	Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis and Rheumatism, 2011, 63, 2192-2202.	6.7	90
39	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Annals of the Rheumatic Diseases, 2010, 69, 1596-1602.	0.9	87
40	Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Annals of the Rheumatic Diseases, 2009, 68, 1585-1590.	0.9	79
41	Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2014, 43, 101-108.	1.1	79
42	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.9	77
43	Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Annals of the Rheumatic Diseases, 2010, 69, 1548-1553.	0.9	75
44	The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial. Annals of the Rheumatic Diseases, 2017, 76, 1603-1606.	0.9	72
45	Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity. Journal of Rheumatology, 2014, 41, 398-406.	2.0	71
46	Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. Annals of the Rheumatic Diseases, 2012, 71, 851-856.	0.9	70
47	Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 321, 461.	7.4	70
48	Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Annals of the Rheumatic Diseases, 2008, 67, 1023-1026.	0.9	68
49	Sex Differences in Response to Anti-Tumor Necrosis Factor Therapy in Early and Established Rheumatoid Arthritis — Results from the DANBIO Registry. Journal of Rheumatology, 2012, 39, 46-53.	2.0	65
50	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Annals of the Rheumatic Diseases, 2012, 71, 374-377.	0.9	64
51	CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'. Arthritis Research and Therapy, 2014, 16, 434.	3.5	61
52	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Annals of the Rheumatic Diseases, 2017, 76, 855-861.	0.9	61
53	Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3Âyears of treatment with TNFα inhibitors. Clinical Rheumatology, 2010, 29, 1301-1309.	2.2	60
54	Fetal Growth and Preterm Birth in Children Exposed to Maternal or Paternal Rheumatoid Arthritis: A Nationwide Cohort Study. Arthritis and Rheumatology, 2014, 66, 3265-3273.	5.6	60

#	Article	IF	CITATIONS
55	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. Annals of the Rheumatic Diseases, 2012, 71, 1942-1949.	0.9	59
56	Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFI± inhibitors in patients with rheumatoid arthritis. Pharmacogenetics and Genomics, 2012, 22, 577-589.	1.5	59
57	Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics Journal, 2016, 16, 141-146.	2.0	58
58	Treatment response and drug retention rates in 24 195 biologic-naÃ⁻ve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.9	58
59	Running induces menstrual disturbances but bone mass is unaffected, except in amenorrheic women. American Journal of Medicine, 1993, 95, 53-60.	1.5	57
60	Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry. Journal of Rheumatology, 2015, 42, 1781-1785.	2.0	56
61	The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology, 2013, 52, 1245-1253.	1.9	55
62	Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome. PLoS ONE, 2014, 9, e100361.	2.5	55
63	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Annals of the Rheumatic Diseases, 2016, 75, 1336-1342.	0.9	55
64	Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry. Clinical Epidemiology, 2017, Volume 9, 627-632.	3.0	55
65	Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Annals of the Rheumatic Diseases, 2015, 74, 2130-2136.	0.9	54
66	Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology, 2016, 55, 659-668.	1.9	53
67	Circulating VEGF As a Biological Marker in Patients with Rheumatoid Arthritis? Preanalytical and Biological Variability in Healthy Persons and in Patients. Disease Markers, 2008, 24, 1-10.	1.3	52
68	Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. European Journal of Endocrinology, 2017, 177, 287-295.	3.7	50
69	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Annals of the Rheumatic Diseases, 2019, 78, 320-327.	0.9	50
70	Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ, The, 2020, 371, m4328.	6.0	50
71	A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases, 2015, 74, 867-875.	0.9	49
72	Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry. RMD Open, 2021, 7, e001505.	3.8	49

#	Article	IF	CITATIONS
73	Comparison of Screening Procedures for <i>Mycobacterium tuberculosis</i> Infection Among Patients with Inflammatory Diseases. Journal of Rheumatology, 2009, 36, 1876-1884.	2.0	47
74	Detection, scoring and volume assessment of bone erosions by ultrasonography in rheumatoid arthritis: comparison with CT. Annals of the Rheumatic Diseases, 2013, 72, 530-534.	0.9	47
75	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.9	47
76	Regional body composition determined by dualâ€energy xâ€ray absorptiometry. Relation to Training, Sex Hormones, and serum lipids in male longâ€distance runners. Scandinavian Journal of Medicine and Science in Sports, 1998, 8, 102-108.	2.9	45
77	Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. Journal of Rheumatology, 2017, 44, 59-69.	2.0	45
78	Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Annals of the Rheumatic Diseases, 2005, 64, 1220-1223.	0.9	44
79	Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis. BMC Medical Genetics, 2018, 19, 165.	2.1	44
80	An open-source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology, 2010, 49, 99-104.	1.9	43
81	Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scandinavian Journal of Rheumatology, 2005, 34, 40-44.	1.1	42
82	Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important?. Journal of Rheumatology, 2010, 37, 285-290.	2.0	42
83	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clinical and Experimental Rheumatology, 2014, 32, 869-77.	0.8	42
84	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	1.9	41
85	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Research and Therapy, 2021, 23, 1.	3.5	41
86	Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Research and Therapy, 2011, 13, R109.	3.5	40
87	Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Annals of the Rheumatic Diseases. 2016, 75, 1645-1653.	0.9	40
88	Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database. Scandinavian Journal of Rheumatology, 2007, 36, 151-154.	1.1	39
89	What Factors Influence the Health Status of Patients with Rheumatoid Arthritis Measured by the SF-12v2 Health Survey and the Health Assessment Questionnaire?. Journal of Rheumatology, 2009, 36, 2183-2189.	2.0	39
90	The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD Open, 2015, 1, e000040-e000040.	3.8	38

Merete L Hetland

#	Article	IF	CITATIONS
91	A Novel ECG-Index for Prediction of Ventricular Arrhythmias in Patients after Myocardial Infarction. , 2014, 19, 330-337.		37
92	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Research and Therapy, 2016, 18, 50.	3.5	37
93	The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arhtritis. Clinical and Experimental Rheumatology, 2012, 30, S44-9.	0.8	37
94	Parental Rheumatoid Arthritis and Autism Spectrum Disorders in Offspring: A Danish Nationwide CohortÂStudy. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 28-32.e1.	0.5	35
95	Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. Journal of Rheumatology, 2018, 45, 53-61.	2.0	35
96	Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology, 2015, 54, kev216.	1.9	34
97	Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0139781.	2.5	34
98	Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PLoS ONE, 2018, 13, e0192010.	2.5	34
99	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology, 2017, 36, 773-779.	2.2	33
100	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	3.8	33
101	Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Annals of the Rheumatic Diseases, 2018, 77, 510-514.	0.9	32
102	Sedentary behaviour in patients with rheumatoid arthritis: A qualitative study. International Journal of Qualitative Studies on Health and Well-being, 2015, 10, 28578.	1.6	31
103	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases, 2018, 77, 1736-1741.	0.9	30
104	DANBIO: a nationwide registry of biological therapies in Denmark. Clinical and Experimental Rheumatology, 2005, 23, S205-7.	0.8	30
105	Detection of rheumatoid arthritis bone erosions by two different dedicated extremity MRI units and conventional radiography. Annals of the Rheumatic Diseases, 2008, 67, 998-1003.	0.9	29
106	Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Annals of the Rheumatic Diseases, 2013, 72, 57-63.	0.9	29
107	Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. Rheumatology, 2019, 58, 110-119.	1.9	29
108	Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, 474.	3.5	28

#	Article	IF	CITATIONS
109	Does low-field dedicated extremity MRI (E-MRI) reliably detect bone erosions in rheumatoid arthritis? A comparison of two different E-MRI units and conventional radiography with high-resolution CT scanning. Annals of the Rheumatic Diseases, 2009, 68, 1296-1302.	0.9	27
110	Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans. PLoS ONE, 2013, 8, e66456.	2.5	27
111	Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology, 2014, 53, 2100-2109.	1.9	27
112	Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. EBioMedicine, 2016, 11, 302-306.	6.1	27
113	Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Annals of the Rheumatic Diseases, 2014, 73, 1123-1129.	0.9	26
114	The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Research and Therapy, 2016, 18, 61.	3.5	26
115	Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials. Annals of the Rheumatic Diseases, 2017, 76. 1707-1715.	0.9	26
116	Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 81-86.	2.0	26
117	Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Annals of the Rheumatic Diseases, 2022, 81, 1085-1095.	0.9	26
118	No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. Clinical Rheumatology, 2007, 26, 1857-1861.	2.2	25
119	Motivational counselling and SMS-reminders for reduction of daily sitting time in patients with rheumatoid arthritis: a descriptive randomised controlled feasibility study. BMC Musculoskeletal Disorders, 2016, 17, 434.	1.9	25
120	Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatology, 2020, 59, 1949-1956.	1.9	24
121	The relationship between age and venous plasma concentrations of noradrenaline, catecholamine metabolites, DOPA and neuropeptide Y-like immunoreactivity in normal human subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 219-224.	1.2	23
122	Galectinâ€3 is Persistently Increased in Early Rheumatoid Arthritis (<scp>RA</scp>) and Associates with Antiâ€ <scp>CCP</scp> Seropositivity and <scp>MRI</scp> Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity. Scandinavian Journal of Immunology, 2017, 86, 471-478.	2.7	23
123	Brief Report: Mâ€Ficolin Levels Reflect Disease Activity and Predict Remission in Early Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 3045-3050.	6.7	22
124	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology, 2015, 54, 1074-1079.	1.9	22
125	Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 8-12.	1.1	22
126	Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy. Cytokine, 2017, 96, 1-7.	3.2	22

#	Article	IF	CITATIONS
127	Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. Scandinavian Journal of Rheumatology, 2018, 47, 465-474.	1.1	22
128	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open, 2019, 5, e000994.	3.8	22
129	Depigmentation ? a rare side effect to intra-articular glucocorticoid treatment. Clinical Rheumatology, 2004, 23, 373-5.	2.2	21
130	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open, 2018, 4, e000655.	3.8	21
131	Sustained Longâ€Term Efficacy of Motivational Counseling and Text Message Reminders on Daily Sitting Time in Patients With Rheumatoid Arthritis: Longâ€Term Followâ€up of a Randomized, Parallelâ€Group Trial. Arthritis Care and Research, 2020, 72, 1560-1570.	3.4	21
132	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology, 2016, 55, 230-236.	1.9	20
133	Mannose-Binding Lectin Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-Cyclic Citrullinated Peptide-Positive Patients with Early Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 731-735.	2.0	19
134	Circulating surfactant protein -D is low and correlates negatively with systemic inflammation in early, untreated rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R39.	3.5	19
135	Quality-Adjusted Life Expectancies in Patients with Rheumatoid Arthritis—Comparison of Index Scores from EQ-5D, 15D, and SF-6D. Value in Health, 2012, 15, 334-339.	0.3	19
136	Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression. Scandinavian Journal of Rheumatology, 2014, 43, 91-100.	1.1	19
137	Effect of Rheumatoid Arthritis on Longterm Sickness Absence in 1994-2011: A Danish Cohort Study. Journal of Rheumatology, 2016, 43, 707-715.	2.0	19
138	Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. Trials, 2017, 18, 161.	1.6	19
139	Long-term sickness absence of 32 chronic conditions: a Danish register-based longitudinal study with up to 17 years of follow-up. BMJ Open, 2018, 8, e020874.	1.9	19
140	Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open, 2018, 4, e000710.	3.8	19
141	Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2019, 48, 1-8.	1.1	19
142	Pregnancy-Induced Changes in Systemic Gene Expression among Healthy Women and Women with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0145204.	2.5	19
143	CD6 and Syntaxin Binding Protein 6 Variants and Response to Tumor Necrosis Factor Alpha Inhibitors in Danish Patients with Rheumatoid Arthritis. PLoS ONE, 2012, 7, e38539.	2.5	18
144	Differentiation between early rheumatoid arthritis patients and healthy persons by conventional and dynamic contrast-enhanced magnetic resonance imaging. Scandinavian Journal of Rheumatology, 2014, 43, 109-118.	1.1	18

#	Article	IF	CITATIONS
145	Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scandinavian Journal of Rheumatology, 2019, 48, 9-16.	1.1	18
146	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Current Medical Research and Opinion, 2019, 35, 1483-1493.	1.9	18
147	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	1.9	18
148	Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark. Rheumatology, 2022, 61, 3711-3722.	1.9	18
149	Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scandinavian Journal of Rheumatology, 2006, 35, 102-106.	1.1	17
150	What Do Patients in Rheumatologic Care Know About the Risks of NSAIDs?. Journal of Clinical Rheumatology, 2008, 14, 69-73.	0.9	17
151	The efficacy of motivational counseling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: protocol for a randomized controlled trial. Trials, 2015, 16, 23.	1.6	17
152	Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1479-1480.	0.9	17
153	A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis. Rheumatology, 2016, 55, 1871-1879.	1.9	17
154	Parental rheumatoid arthritis and childhood epilepsy. Neurology, 2016, 87, 2510-2516.	1.1	17
155	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. Journal of Rheumatology, 2017, 44, 162-169.	2.0	17
156	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naÃ ⁻ ve patients with spondyloarthritis. RMD Open, 2019, 5, e001079.	3.8	17
157	Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open, 2019, 5, e001016.	3.8	17
158	The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis. ClinicoEconomics and Outcomes Research, 2010, 2, 105.	1.9	16
159	Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. Arthritis Research and Therapy, 2017, 19, 80.	3.5	16
160	The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 570.	1.6	16
161	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology, 2019, 58, 874-883.	1.9	16
162	Changes in Plasma IL-6, Plasma VEGF and Serum YKL-40 During Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy. Biomarker Insights, 2009, 4, BMI.S2300.	2.5	15

#	Article	IF	CITATIONS
163	New remission criteria for RA: â€~modern times' in rheumatology—not a silent film, rather a 3D movie. Annals of the Rheumatic Diseases, 2011, 70, 401-403.	0.9	15
164	Patterns of Magnetic Resonance Imaging Bone Erosion in Rheumatoid Arthritis — Which Bones Are Most Frequently Involved and Show the Most Change?: Figure 1 Journal of Rheumatology, 2011, 38, 2014-2017.	2.0	15
165	Monitoring total-body inflammation and damage in joints and entheses: the first follow-up study of whole-body magnetic resonance imaging in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2017, 46, 253-262.	1.1	15
166	Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clinical Rheumatology, 2017, 36, 781-789.	2.2	15
167	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1889-1893.	2.0	15
168	Patients' Views on Routine Collection of Patientâ€Reported Outcomes in Rheumatology Outpatient Care: A Multicenter Focus Group Study. Arthritis Care and Research, 2020, 72, 1331-1338.	3.4	15
169	<scp>Oneâ€Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care and Research, 2022, 74, 748-758.	3.4	15
170	Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission. Arthritis Research and Therapy, 2021, 23, 48.	3.5	15
171	Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. Clinical and Experimental Rheumatology, 2015, 33, 498-502.	0.8	15
172	Cartilage Oligomeric Matrix Protein Associates Differentially with Erosions and Synovitis and Has a Different Temporal Course in Cyclic Citrullinated Peptide Antibody (Anti-CCP)-positive versus Anti-CCP-negative Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 1563-1568.	2.0	14
173	Parental rheumatoid arthritis and long-term child morbidity: a nationwide cohort study. Annals of the Rheumatic Diseases, 2016, 75, 1831-1837.	0.9	14
174	Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. Scandinavian Journal of Rheumatology, 2017, 46, 353-358.	1.1	14
175	The Dâ€vitamin metabolite 1,25(<scp>OH</scp>) ₂ D in serum is associated with disease activity and Anti itrullinated Protein Antibodies in active and treatment naÃīve, early Rheumatoid Arthritis Patients. Scandinavian Journal of Immunology, 2018, 88, e12704.	2.7	14
176	Intake of dietary fibre, red and processed meat and risk of late-onset Chronic Inflammatory Diseases: A prospective Danish study on the "diet, cancer and health―cohort. International Journal of Medical Sciences, 2020, 17, 2487-2495.	2.5	14
177	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. Scientific Reports, 2020, 10, 4316.	3.3	14
178	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	1.9	14
179	Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database. Clinical and Experimental Rheumatology, 2010, 28, 820-7.	0.8	14
180	Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clinical and Experimental Rheumatology, 2014, 32, S-141-6.	0.8	14

#	Article	IF	CITATIONS
181	Uncoupling of Collagen II Metabolism in Newly Diagnosed, Untreated Rheumatoid Arthritis Is Linked to Inflammation and Antibodies Against Cyclic Citrullinated Peptides. Journal of Rheumatology, 2010, 37, 1113-1120.	2.0	13
182	Which Factors Influence Radiographic Progression During Treatment with Tumor Necrosis Factor Inhibitors in Clinical Practice? Results from 930 Patients with Rheumatoid Arthritis in the Nationwide Danish DANBIO Registry. Journal of Rheumatology, 2014, 41, 2352-2360.	2.0	13
183	Work ability in rheumatoid arthritis patients: a register study on the prospective risk of exclusion and probability of returning to work. Rheumatology, 2017, 56, 1135-1143.	1.9	13
184	Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. BMJ Open, 2018, 8, e019325.	1.9	13
185	Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. BMJ Open, 2019, 9, e028197.	1.9	13
186	Validation and assessment of minimally clinically important difference of the unadjusted Health Assessment Questionnaire in a Danish cohort: uncovering ordinal bias. Scandinavian Journal of Rheumatology, 2020, 49, 1-7.	1.1	13
187	Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, annrheumdis-2021-219951.	0.9	13
188	CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. Arthritis Research and Therapy, 2014, 16, 475.	3.5	12
189	Interleukin-23 in early disease development in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2015, 44, 438-442.	1.1	12
190	Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response. PLoS ONE, 2016, 11, e0148486.	2.5	12
191	Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish <scp>DANBIO</scp> Registry Emulating a Randomized Trial. Arthritis and Rheumatology, 2019, 71, 1997-2004.	5.6	12
192	Gain in Quality-adjusted Life-years in Patients with Rheumatoid Arthritis During 1 Year of Biological Therapy: A Prospective Study in Clinical Practice. Journal of Rheumatology, 2013, 40, 1479-1486.	2.0	11
193	FRI0298â€The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries. Annals of the Rheumatic Diseases, 2014, 73, 492.3-493.	0.9	11
194	Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. Trials, 2015, 16, 178.	1.6	11
195	Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 385-389.	1.2	11
196	Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients. Scandinavian Journal of Rheumatology, 2019, 48, 178-184.	1.1	11
197	Rheumatoid arthritis and risk of spontaneous abortion: a Danish nationwide cohort study. Rheumatology, 2020, 59, 1984-1991.	1.9	11
198	Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission. Rheumatology, 2021, 60, 5549-5559.	1.9	11

#	Article	IF	CITATIONS
199	Keitel Functional Test for Patients With Rheumatoid Arthritis: Translation, Reliability, Validity, and Responsiveness. Physical Therapy, 2008, 88, 664-678.	2.4	10
200	Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Scandinavian Journal of Rheumatology, 2018, 47, 259-269.	1,1	10
201	Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. Scandinavian Journal of Rheumatology, 2019, 48, 128-132.	1.1	10
202	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics Journal, 2019, 19, 83-96.	2.0	10
203	Programmed death ligand 2 – A link between inflammation and bone loss in rheumatoid arthritis. Journal of Translational Autoimmunity, 2020, 3, 100028.	4.0	10
204	One measurement of serum total cholesterol is enough to predict future levels in healthy postmenopausal women. American Journal of Medicine, 1992, 92, 25-28.	1.5	9
205	Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study. Arthritis Research and Therapy, 2017, 19, 104.	3.5	9
206	Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. Annals of the Rheumatic Diseases, 2022, 81, 789-797.	0.9	9
207	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings. Frontiers in Immunology, 2022, 13, 773946.	4.8	9
208	Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naA¬ve rheumatoid arthritis patients is up-regulated and not influenced by 1Âyear of clinically effective treatment. Rheumatology International, 2012, 32, 501-504.	3.0	8
209	Decreases in diagnostic delay are supported by sensitivity analyses. Annals of the Rheumatic Diseases, 2014, 73, e45-e45.	0.9	8
210	Physical activity behaviour in men with inflammatory joint disease: a cross-sectional register-based study. Rheumatology, 2018, 57, 803-812.	1.9	8
211	Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. Scandinavian Journal of Rheumatology, 2018, 47, 418-421.	1.1	8
212	Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS). Journal of Rheumatology, 2019, 46, 1222-1227.	2.0	8
213	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open, 2020, 6, e001363.	3.8	8
214	Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis. Scientific Reports, 2020, 10, 7371.	3.3	8
215	Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis. Rheumatology, 2021, 60, SI3-SI12.	1.9	8
216	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Seminars in Arthritis and Rheumatism, 2021, 51, 1108-1112.	3.4	8

#	Article	IF	CITATIONS
217	Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry. Clinical and Experimental Rheumatology, 2016, 34, S75-S78.	0.8	8
218	Increase in plasma 3,4-dihydroxyphenylalanine (DOPA) appearance rate after inhibition of DOPA decarboxylase in humans. European Journal of Clinical Investigation, 1994, 24, 205-211.	3.4	7
219	OP0274â€Towards imaging remission: Determining a MRI inflammatory activity acceptable state in rheumatoid arthritis:. Annals of the Rheumatic Diseases, 2013, 71, 149.2-149.	0.9	7
220	Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs—a cohort study. Rheumatology, 2016, 55, 1017-1022.	1.9	7
221	FRI0190â€Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry. , 2017, , .		7
222	Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). Scandinavian Journal of Rheumatology, 2017, 46, 335-345.	1.1	7
223	Psoriatic arthritis: still room for improvement. Lancet, The, 2020, 395, 1463-1465.	13.7	7
224	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14Â868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	1.9	7
225	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). Journal of Rheumatology, 2020, 47, 658-667.	2.0	7
226	Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2022, , 1-9.	1.1	7
227	Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis – data from the Danish nationwide DANBIO registry. Seminars in Arthritis and Rheumatism, 2022, 52, 151948.	3.4	7
228	European bio-naÃ ⁻ ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	1.9	7
229	Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. Scandinavian Journal of Rheumatology, 2017, 46, 441-445.	1.1	6
230	Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology, 2021, 60, 380-391.	1.9	6
231	Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry. RMD Open, 2021, 7, e001649.	3.8	6
232	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Frontiers in Immunology, 2021, 12, 672255.	4.8	6
233	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	1.9	6
234	Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatology, 2023, 62, 647-658.	1.9	6

#	Article	IF	CITATIONS
235	Body composition and serum lipids in female runners: influence of exercise level and menstrual bleeding pattern. European Journal of Clinical Investigation, 1995, 25, 553-558.	3.4	5
236	Contact Frequency, Travel Time, and Travel Costs for Patients with Rheumatoid Arthritis. International Journal of Rheumatology, 2014, 2014, 1-9.	1.6	5
237	FRIO322â€Positivity for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide is Associated with A Better Drug Retention of Abatacept: Data from A Paneuropean Analysis of RA Registries. Annals of the Rheumatic Diseases, 2014, 73, 502.2-503.	0.9	5
238	FRIO313â€Body Mass Does not Affect Clinical Outcomes of Therapy with Abatacept in Rheumatoid Arthritis (RA) Patients. A Pan-European Analysis of RA Registries. Annals of the Rheumatic Diseases, 2014, 73, 498.3-499.	0.9	5
239	Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study. Arthritis Research and Therapy, 2016, 18, 53.	3.5	5
240	Impact of red meat, processed meat and fibre intake on risk of late-onset chronic inflammatory diseases: prospective cohort study on lifestyle factors using the Danish †Diet, Cancer and Health' cohort (PROCID-DCH): <i>protocol</i> . BMJ Open, 2019, 9, e024555.	1.9	5
241	Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. Scandinavian Journal of Rheumatology, 2019, 48, 17-23.	1.1	5
242	Association between MRI findings and patientâ€reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse. International Journal of Rheumatic Diseases, 2020, 23, 488-498.	1.9	5
243	Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model. Rheumatology, 2021, 60, 3834-3844.	1.9	5
244	Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1512-1518.	2.0	5
245	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research and Therapy, 2021, 23, 189.	3.5	5
246	CXCL13 predicts long-term radiographic status in early rheumatoid arthritis. Rheumatology, 2022, 61, 2590-2595.	1.9	5
247	OP0168â€Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor 1± therapy: Results from the danish nationwide danbio registry. Annals of the Rheumatic Diseases, 2013, 71, 111.2-111.	0.9	4
248	Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-record evaluated outcomes. BMJ Open, 2017, 7, e014816.	1.9	4
249	Motivational Counseling and Text Message Reminders. Rheumatic Disease Clinics of North America, 2019, 45, 231-244.	1.9	4
250	Risk factors for <i>Staphylococcus aureus</i> bacteremia in patients with rheumatoid arthritis and incidence compared with the general population: protocol for a Danish nationwide observational cohort study. BMJ Open, 2019, 9, e030999.	1.9	4
251	Folinic acid alleviates side effects of methotrexate in arthritis patients with side effects despite folic acid supplementation: an observational cohort study. Rheumatology, 2020, 59, 3566-3568.	1.9	4
252	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: aÂNordic population-based cohort study. Rheumatology, 2021, 60, 140-146.	1.9	4

#	Article	IF	CITATIONS
253	Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial. Rheumatology International, 2021, 41, 543-549.	3.0	4
254	Tapering of TNF inhibitors in axial spondyloarthritis in routine care — 2-year clinical and MRI outcomes and predictors of successful tapering. Rheumatology, 2021, , .	1.9	4
255	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 0, , .	0.8	4
256	Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—An Interim Report from a Danish Prospective Cohort Study. Vaccines, 2022, 10, 35.	4.4	4
257	Risk of <i>Staphylococcus aureus</i> bacteraemia in patients with rheumatoid arthritis and the effect of orthopaedic implants on the risk: a nationwide observational cohort study. Scandinavian Journal of Rheumatology, 2023, 52, 250-258.	1.1	4
258	SAT0383â€Using MRI synovitis to count involved joints in the ACR/EULAR 2010 RA criteria increases their sensitivity and specificity. Annals of the Rheumatic Diseases, 2013, 71, 601.2-601.	0.9	3
259	SAT0409â€Association between Tobacco Smoking and Response to Tumor Necrosis Factor Alpha Inhibitor Treatment in Psoriatic Arthritis: Results from the Danbio Registry. Annals of the Rheumatic Diseases, 2014, 73, 743.1-743.	0.9	3
260	AB1053â€The Nationwide Danish Rheumatologic Biobank – Paving The Road To Personalized Treatment of Patients with Inflammatory Rheumatic Diseases. Annals of the Rheumatic Diseases, 2016, 75, 1262.1-1262.	0.9	3
261	FRI0378â€DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT? â€" RESULTS FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		3
262	Response to: â€~Mandatory, cost-driven switching from originator etanercept to its biosimilar SB ₄ : possible fallout on non-medical switching' by Cantini and Benucci. Annals of the Rheumatic Diseases, 2020, 79, e14-e14.	0.9	3
263	Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries. Annals of the Rheumatic Diseases, 2020, 79, 846-848.	0.9	3
264	Characteristics of participants and decliners from a randomized controlled trial on physical activity in patients with rheumatoid arthritis: a retrospective register-based cross-sectional study. Scandinavian Journal of Rheumatology, 2023, 52, 17-24.	1.1	3
265	Modern treatment strategies in rheumatoid arthritis. Danish Medical Bulletin, 2011, 58, B4320.	0.3	3
266	OP0028â€Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration. Annals of the Rheumatic Diseases, 2013, 71, 62.2-62.	0.9	2
267	Reply to eLetter by Feldtkeller <i>et al</i> . Annals of the Rheumatic Diseases, 2014, 73, e78-e78.	0.9	2
268	FRI0169â€Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration. Annals of the Rheumatic Diseases, 2015, 74, 484.2-485.	0.9	2
269	FRIO518â€Prescription patterns of tumour necrosis factor inhibitor and ustekinumab in psoriatic arthritis: a nordic population-based cohort study. , 2017, , .		2
270	The Rheumatoid Arthritis Gene Expression Signature Among Women Who Improve or Worsen During Pregnancy: A Pilot Study. Journal of Rheumatology, 2021, 48, 985-991.	2.0	2

#	Article	IF	CITATIONS
271	Whole-Body Magnetic Resonance Imaging Assessment of Joint Inflammation in Rheumatoid Arthritis—Agreement With Ultrasonography and Clinical Evaluation. Frontiers in Medicine, 2020, 7, 285.	2.6	2
272	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. Annals of the Rheumatic Diseases, 2012, 71, A13.2-A14.	0.9	2
273	FRI0103â€One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study. , 2018, , .		2
274	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology, 2022, 61, 4286-4296.	1.9	2
275	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology, 2022, 61, 3647-3656.	1.9	2
276	FRI0017â€Ox40 and ox40I are highly associated with autoantibody formation in early rheumatoid arthritis, and predict flare after anti-tnf discontinuation Annals of the Rheumatic Diseases, 2013, 72, A374.1-A374.	0.9	1
277	OP0162â€Prevalence of Comorbidities in Rheumatoid Arthritis. Does Gross Domestic Product Matter? Results from 34 Countries in the QUEST-RA Program. Annals of the Rheumatic Diseases, 2013, 72, A107.1-A107.	0.9	1
278	OP0223â€M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naÃ⁻ve rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 131.1-131.	0.9	1
279	THU0086â€Seropositivity and response to RTX: Data from the cererra collaboration:. Annals of the Rheumatic Diseases, 2013, 71, 182.1-182.	0.9	1
280	SAT0036â€Retention of Tocilizumab Therapy: A Comparison between Tocilizumab in Monotherapy and in Combination with DMARDS Based on the Tocerra Collaboration. Annals of the Rheumatic Diseases, 2014, 73, 601.3-602.	0.9	1
281	FRI0595-HPRâ€Reduction of Sedentary Behaviour in Patients with Rheumatoid Arthritis. A Randomized Feasibility Study. Annals of the Rheumatic Diseases, 2014, 73, 1210.2-1210.	0.9	1
282	THU0260â€Delay in RA Diagnosis of More than 12 Months is Associated with Deteriorated Functional Status in Patients in Bdmard Treatment– Results from A Prospective Study. Annals of the Rheumatic Diseases, 2014, 73, 273.1-273.	0.9	1
283	FRIOO42â€Validation of A Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis in Relation to Imaging Inflammation and Damage. Annals of the Rheumatic Diseases, 2014, 73, 396.2-396.	0.9	1
284	FRIOO47â€The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission. Annals of the Rheumatic Diseases, 2015, 74, 435.3-436.	0.9	1
285	FRIO607â€Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial, Annals of the Rheumatic Diseases, 2015, 74, 648,1-648.	0.9	1
286	THU0127â€Development of Draft Criteria for Arthralgia that is Clinically Suspect for Progression to Rheumatoid Arthritis; Results of Phase 1. Annals of the Rheumatic Diseases, 2015, 74, 240.1-240.	0.9	1
287	FRIOO67â€Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study. Annals of the Rheumatic Diseases, 2016, 75, 450.1-450.	0.9	1
288	THU0123â€Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry. Annals of the Rheumatic Diseases, 2016, 75, 224.2-224.	0.9	1

#	Article	IF	CITATIONS
289	OP0225â€Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis. Results from The Danbio Registry: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 142.2-142.	0.9	1
290	THU0246â€Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified disease activity index for psoriatic arthritis (DAPSA) based on 28 joints?. , 2018, , .		1
291	OP0018â€The value of adding mri to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial. , 2018, , .		1
292	THU0667â€OVERALL INFECTION RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ABATACEPT, RITUXIMAB AND TOCILIZUMAB. AN OBSERVATIONAL COHORT STUDY. , 2019, , .		1
293	FRI0404â€POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .		1
294	AB1174â€IS MONITORING SYNOVITIS IN THE HANDS BY ULTRASOUND ENOUGH TO ASSESS TREATMENT EFFECTIN PATIENTS WITH RA IN CLINICAL PRACTICE?. , 2019, , .	СТ	1
295	OP0017â€VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR ANTI-TNF DRUG RESPONSE IN RHEUMATOID ARTHRITIS: A META-ANALYSIS OF THREE LARGE COHORTS. Annals of the Rheumatic Diseases, 2021, 80, 9.2-10.	0.9	1
296	OPO219-HPRâ€The efficacy of motivational counselling and sms-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial. , 2018, , .		1
297	Response to â€ã€To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al. Annals of the Rheumatic Diseases, 2020, 79, e37-e37.	0.9	1
298	MON-179 Association Between Long-Term Prednisolone Induced Adrenal Insufficiency and Polymorphisms in the Glucocorticoid Receptor Gene. Journal of the Endocrine Society, 2020, 4, .	0.2	1
299	Conversion of the MDHAQ to the HAQ score—a simple algorithm developed and validated in a cohort of 13,391 real-world patients. Rheumatology, 2022, , .	1.9	1
300	Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis. Scientific Reports, 2022, 12, 4670.	3.3	1
301	Origin and Significance of Plasma Dihydroxyphenylalanine. Advances in Pharmacology, 1997, 42, 851-854.	2.0	0
302	Management of Rheumatoid Arthritis. , 2010, , 1-16.		0
303	Gain in Quality-adjusted Life-years in Patients with Rheumatoid Arthritis During 1 Year of Biological Therapy: A Prospective Study in Clinical Practice. Journal of Rheumatology, 2013, 40, 1634.2-1634.	2.0	0
304	AB0316â€Patient's global assessment of general health by vas at baseline predicts ACR/EULAR remission after 3, 6 and 12 month's of efficient treatment in DMARD- and steroid naÃve early rheumatoid arthritis patients. The danish cimestra-study. Annals of the Rheumatic Diseases, 2013, 71, 655.12-655.	0.9	0
305	AB0057â€Soluble pd-1 and spd-l2 are unaffected by adalimumab treatment in early ra and associated with presence of anti-ccp and igm-rf. Annals of the Rheumatic Diseases, 2013, 72, A803.1-A803.	0.9	0
306	SP0176â€Measuring outcomes in a busy practice. Annals of the Rheumatic Diseases, 2013, 71, 43.2-43.	0.9	0

#	Article	IF	CITATIONS
307	FRIOO63â€How is fatigue associated with comorbidity burden, disease activity, and disability in patients with rheumatoid arthritis? results from 34 countries in the quest-ra program. Annals of the Rheumatic Diseases, 2013, 72, A389.2-A390.	0.9	0
308	FRI0148â€Remission rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis - 1-year results of investigator-initiated, double-blinded randomized clinical trial (OPERA):. Annals of the Rheumatic Diseases, 2013, 71, 360.3-361.	0.9	0
309	SAT0391â€Does dynamic contrast-enhanced mri provide better separation of active early rheumatoid arthritis patients and healthy controls than conventional MRI?:. Annals of the Rheumatic Diseases, 2013, 71, 604.2-605.	0.9	0
310	SAT0065â€Effectiveness and Drug Adherence of Biologic Monotherapy in Danish Rheumatoid Arthritis Patients: A Cohort Study of Clinical Practice in the Danbio Registry. Annals of the Rheumatic Diseases, 2014, 73, 613.2-614.	0.9	0
311	THU0550â€Changes in Soluble CD18 Reflect Latency in Restoration of the Immune System after Early Treatment of Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 373.1-373.	0.9	0
312	AB0001â€Genotype and Haplotype Effects of 7 Single-Nucleotide Polymorphisms in the CRP Gene on Levels of C-Reactive Protein and DAS28 in Two Cohorts of Treatment NaÃVe, Recent Onset Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2014, 73, 804.1-804.	0.9	0
313	THU0478â€Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors. Annals of the Rheumatic Diseases, 2014, 73, 348.3-348.	0.9	0
314	OP0075â€Impact of Different Infliximab Dose Regimens on Treatment Response and Drug Survival in 462 Patients with PSA. Results from the Nationwide Registries Danbio and Icebio. Annals of the Rheumatic Diseases, 2014, 73, 89.1-89.	0.9	0
315	FRI0328â€Fixed versus On-Flare Retreatment with Rituximab in RA – Results from the Cererra Collaboration. Annals of the Rheumatic Diseases, 2014, 73, 505-506.	0.9	0
316	SAT0229 \hat{a} €Effectiveness of Repeated Courses of Rituximab in RA \hat{a} €" Results from the Cererra Collaboration. Annals of the Rheumatic Diseases, 2014, 73, 674.1-674.	0.9	0
317	OP0256â€ADAM17 And Galectin-9 are Critical Regulators of Local 4-1BB Activity and Disease Outcome in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 168.3-169.	0.9	0
318	OP0073â€Polymorphisms in the FCN1 Gene Coding for M-Ficolin are Associated with Disease Activity, Radiographic Damage and are the Strongest Predictors of DAS28 Remission in 180 DMARD Naive Early Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2015, 74, 96.1-96.	0.9	0
319	THU0241â€Association Between Tobacco Smoking and Response to Tumor Necrosis Factor Alpha Inhibitor Treatment in Ankylosing Spondylitis: Results from the Danish Nationwide Danbio Registry. Annals of the Rheumatic Diseases, 2015, 74, 284-285.	0.9	0
320	SAT0003â€The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Rheumatoid Arthritis-Associated Autoantibodies and Radiographic Progression. Annals of the Rheumatic Diseases, 2015, 74, 650.3-651.	0.9	0
321	THU0305â€Fatigue is Correlated to Pain Mechanism Rather than to Inflammatory Load in Patients with Rheumatoid Arthritis: A Descriptive Cross-Sectional Danbio Registry Survey. Annals of the Rheumatic Diseases, 2015, 74, 306.2-306.	0.9	0
322	THU0326â€Pain Mechanisms in Patients with Inflammatory Arthritis: A Nationwide Cross-Sectional Danbio Registry Survey. Annals of the Rheumatic Diseases, 2015, 74, 313.2-313.	0.9	0
323	FRI0134â€Risk of Virus-Associated Malignancies in Female Arthritis Patients Treated with Biological DMARDs:. Annals of the Rheumatic Diseases, 2015, 74, 470.1-470.	0.9	0
324	AB1076â€Ultrasound Abnormalities at the Entheses are not an Uncommon Finding in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1260.1-1260.	0.9	0

#	Article	IF	CITATIONS
325	AB0440â€The Impact of Patient Characteristics and Past Treatment History on the Evolution of Functional Disability in RA Patients Treated with Abatacept. A Pan-European Analysis of RA Registries. Annals of the Rheumatic Diseases, 2015, 74, 1041.3-1042.	0.9	0
326	SAT0079â€Tumour Necrosis Factor Alpha Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry. Annals of the Rheumatic Diseases, 2015, 74, 677.1-677.	0.9	0
327	AB1183â€Joint Operations as an Indicator of Disease Severity and Burden in the Quest-RA Study: Table 1 Annals of the Rheumatic Diseases, 2015, 74, 1298.2-1299.	0.9	0
328	FRI0187â€Rituximab Done! What's Next in Rheumatoid Arthritis? A European Observational Longitudinal Study Assessing the Effectiveness of Biologics After Rituximab Treatment in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 492.1-492.	0.9	0
329	SAT0610â€The Prospective Risk for Long Term Sickness Absence, Unemployment, and Disability Pension, and The Probability for Return To Work in Patients with Rheumatoid Arthritis:. Annals of the Rheumatic Diseases, 2016, 75, 890.2-890.	0.9	0
330	AB0263â€Agreement between Das28, Acr/eular, Sdai, Cdai and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care. Annals of the Rheumatic Diseases, 2016, 75, 989.2-990.	0.9	0
331	FRIO547â€Magnetic Resonance Imaging Joint Space Narrowing Is An Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 638.2-638.	0.9	Ο
332	OP0286-HPRâ€The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial. Annals of the Rheumatic Diseases, 2016, 75, 166.2-166.	0.9	0
333	FRI0070â€Trajectories of Disease Activity in Rheumatoid Arthritis Patients after Abatacept Initiation and Their Association with Clinical Characteristics. Annals of the Rheumatic Diseases, 2016, 75, 451.2-452.	0.9	Ο
334	AB0204â€Glucocorticoid-Sparing Effects of Abatacept in Rheumatoid Arthritis Are Associated with both Abatacept Effectiveness and Seropositivity. Annals of the Rheumatic Diseases, 2016, 75, 967.1-967.	0.9	0
335	SAT0052â€Is Information about The Reason for Previous Biologics Discontinuation Useful To Predict The Effectiveness of A Biologic with A Different Mode of Action?. Annals of the Rheumatic Diseases, 2016, 75, 682.2-682.	0.9	0
336	FRI0581â€Validation of The Danish Version of The Stanford Health Assessment Questionnaire Disability Index and Determination of The Minimal Clinically Important Difference in A Cohort of Rheumatoid Arthritis Patients Using The Rasch Measurement Model. Annals of the Rheumatic Diseases, 2016, 75, 652.1-652.	0.9	0
337	FRI0535â€Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment. A Substudy of The Optimized Treatment Algorithm in Early RA (Opera) Trial. Annals of the Rheumatic Diseases, 2016, 75, 633.1-633.	0.9	0
338	AB0036â€Soluble CD83 Plasma Levels Are Associated with Disease Activity and Course of Disease in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 909.1-909.	0.9	0
339	SAT0371â€Hla-B27 Status Is Associated with tnfα Inhibitor Treatment Outcomes in Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis – Observational Cohort Study from The Nationwide Danbio Registry. Annals of the Rheumatic Diseases, 2016, 75, 801.1-801.	0.9	0
340	Parental Rheumatoid Arthritis, Child Mortality, and Case Fatality: A Nationwide Cohort Study. Arthritis Care and Research, 2017, 69, 933-937.	3.4	0
341	THU0361â€Prescription patterns of biological disease modifying drugs and biosimilars in ankylosing spondylitis – a collaboration between biological registers in the five nordic countries. , 2017, , .		0
342	FRIO450â€Commonalities and differences in data collection across european spondyloarthritis		0

registries. , 2017, , .

#	Article IF	CITATIONS
343	SAT0045â€11 years' follow-up of a danish 2-year treat-to-target randomized controlled trial in patients with early rheumatoid arthritis: baseline predictors of functional and radiographic outcomes. , 2017, ,	0
344	FRI0641â€Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: long-term results from two randomized controlled trials. , 2017, , .	0
345	THU0091â€High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies. , 2017, , .	0
346	THU0662â€Comparing electronic collection of patient reported outcomes at home versus touch-screens in the waiting area among patients with arthritis in clinical practice: a randomised agreement study with online recruitment using danbio. , 2017, , .	0
347	FRIO221â€Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?. , 2017, , .	0
348	THU0649â€Mandatory choice of first bdmard in denmark – an opportunity to study real-life effectiveness? results from the danbio registry. , 2017, , .	0
349	FRI0628â€Ultrasound shows signs of inflammation in most patients with rheumatoid arthritis in longstanding clinical remission, irrespective of conventional synthetic or biologic dmard therapy. , 2017, , .	0
350	THU0648â€Use of outpatient rheumatologic health care services before and after switch from originator to biosimilar infliximab. , 2017, , .	0
351	OP0149â€An mri guided treat-to-target strategy in rheumatoid arthritis patients in clinical remission improved mri inflammation but not damage progression – results from the imagine-ra randomised controlled trial. , 2018, , .	Ο
352	OP0331â€MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION. , 2019, , .	0
353	FRI0679â€PREDICTORS OF DEATH IN 3693 PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWED FOR UP TO 12 YEARS IN CLINICAL PRACTICE. , 2019, , .	0
354	FRI0403â€HIGH BASELINE PATIENT'S COMPARED WITH EVALUATOR'S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS – DATA FROM THE EUROSPA COLLABORATION. , 2019, , .	0
355	SAT0092â€LOW SERUM LEVEL OF VITAMIN D AT TIME OF DIAGNOSIS IS ASSOCIATED WITH HIGHER ONE-YEAR REMISSION RATE IN PATIENTS WITH NEWLY DIAGNOSED RA, TREATED AGGRESSIVELY DURING FOLLOW-UP: POST-HOC ANALYSES OF THE CIMESTRA TRIAL. , 2019, , .	Ο
356	AB0752â€DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÃVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION. , 2019, , .	0
357	SAT0365â€SECULAR CHANGES IN PSORIATIC ARTHRITIS PATIENTS STARTING FIRST COURSE OF BIOLOGIC THERAPIES – INFLAMMATORY HALLMARKS OF LESSER PROMINENCE: A NORDIC POPULATION-BASED COHORT STUDY. , 2019, , .	Ο
358	SAT0391â€REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK. , 2019, , .	0
359	THU0134â€COMORBIDITIES IN >5000 PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING TREATMENT WITH METHOTREXATE IN ROUTINE CARE: PREVALENCE AND IMPACT ON TREATMENT OUTCOMES. AN OBSERVATIONAL COHORT STUDY FROM DANBIO. , 2019, , .	0
360	SATOOO6â€T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM-3) IS INCREASED IN ACTIVE RHEUMATOID ARTHRITIS AND ASSOCIATED WITH CLINICAL DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION. , 2019, , .	0

#	Article	IF	CITATIONS
361	THU0065â€VALIDATION OF THE ADJUSTED MULTI-BIOMARKER DISEASE ACTIVITY SCORE FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION FOR PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
362	FRIO082â€EFFECTIVENESS OF TNF INHIBITORS VS. NON-TNF INHIBITORS (ABATACEPT, TOCILIZUMAB AND) TJ E BETWEEN FIVE NATIONAL REGISTERS. , 2019, , .	TQq0 0 0	rgBT /Overlc 0
363	FRI0453â€DOES DISCORDANCE BETWEEN BASELINE PATIENT'S AND EVALUATOR'S GLOBAL ASSESSME DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS? DATA FROM THE EUROSPA RESEARCH COLLABORATION. , 2019, , .	ENT OF	0
364	OP0266â€RISK OF HOSPITALIZED INFECTION IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS TREATED WITH BIOLOGICAL DRUGS – A MATCHED COHORT STUDY. , 2019, , .)	0
365	FRI0377â€IDENTICAL TWO-YEAR TREATMENT RETENTION OF ORIGINATOR AND BIOSIMILAR INFLIXIMAB. RESUL OF A NORDIC COLLABORATION INCLUDING 1319 PATIENTS WITH SPONDYLOARTHRITIS. , 2019, , .	.TS	0
366	OP0236â€SIMILAR ONE-YEAR TREATMENT RETENTION OF ORIGINATOR AND BIOSIMILAR ETANERCEPT. RESULT OF A NORDIC COLLABORATION INCLUDING 1015 PATIENTS WITH SPONDYLOARTHRITIS. , 2019, , .	S	0
367	OP0220â€SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES IN 17453 BIONAÃVE PSORIATIC ARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION. Annals of the Rheumatic Diseases, 2021, 80, 131.2-132.	N 0.9	0
368	OP0140â€BIOLOGIC REFRACTORY DISEASE IN AXIAL SPONDYLOARTHRITIS - DEFINITION, PREVALENCE AND PATIENT CHARACTERISTICS. A COLLABORATION BETWEEN FIVE NORDIC BIOLOGIC REGISTRIES. Annals of the Rheumatic Diseases, 2021, 80, 82-83.	0.9	0
369	POS0454â€COMPARISON OF MBDA SCORE, PATIENT GLOBAL ASSESSMENT AND EVALUATOR GLOBAL ASSESSMENT FOR PREDICTING RISK OF RADIOGRAPHIC PROGRESSION. Annals of the Rheumatic Diseases, 2021, 80, 457-458.	0.9	0
370	OP0222â€THE INCIDENCE OF INTERSTITIAL LUNG DISEASE IN PSORIATIC ARTHRITIS COMPARED TO RHEUMATO ARTHRITIS. DATA FROM OVER 89 000 BDMARD TREATMENT COURSES DERIVED FROM FIVE NORDIC REGISTERS. Annals of the Rheumatic Diseases, 2021, 80, 133-134.	DID 0.9	0
371	Participant evaluation of a behavioral intervention targeting reduction of sedentary behavior in patients with rheumatoid arthritis: a mixed methods study. Disability and Rehabilitation, 2021, , 1-12.	1.8	0
372	Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. Scandinavian Journal of Rheumatology, 2021, , 1-11.	1.1	0
373	Rheumatology: Biosimilars are here to stay. Rheumatology, 2021, , .	1.9	0
374	ls gene expression among women with rheumatoid arthritis dysregulated during a postpartum flare?. Arthritis Research and Therapy, 2021, 23, 30.	3.5	0
375	THU0189â€One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. , 2018, , .		0
376	FRIO110â€The impact of seropositivity on the effectiveness of abatacept versus tnf inhibitors in rheumatoid arthritis. real life data from several european registries (THE PAN-ABA STUDY). , 2018, , .		0
377	OP0328-HPRâ€Patients' views on routine collection of patient-reported outcomes in rheumatology care – a danbio focus group study. , 2018, , .		0
378	SAT0291â€Creation of a european database of patients with axial spondyloarthritis treated in clinical practice– initial, preliminary findings from the eurospa research network collaboration. , 2018, , .		0

#	Article	IF	CITATIONS
379	THU0317â€Creating a european database of psoriatic arthritis patients treated in routine care – first, preliminary results from the eurospa research network collaboration. , 2018, , .		0
380	OP0214â€Baseline comorbidities and overweight predict functional status and health-related quality of life 9 years later – a longitudinal cohort study of 428 patients with rheumatoid arthritisreceiving standard care. , 2018, , .		0
381	THU0010â€Polymorphisms in phase i-metabolising enzyme and hormone receptor genes influence the response to anti-tnf therapy. , 2018, , .		0
382	OP0038â€Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in remission in routine care – 2-year outcomes and identification of predictors. , 2018, , .		0
383	AB0209â€PREDICTORS OF ACHIEVING STRINGENT REMISSION IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY. Annals of the Rheumatic Diseases, 2020, 79, 1405.2-1405.	0.9	0
384	FRI0019â€MRI INFLAMMATION, DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT ARE MORE EFFECTIVELY REDUCED BY ESCALATION TO BIOLOGICS COMPARED TO CSDMARD-ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION FOLLOWING A TREAT-TO-TARGET STRATEGY: SECONDARY ANALYSES OF THE IMAGINE-RA TRIAL. Annals of the Rheumatic Diseases, 2020, 79, 581-582.	0.9	0
385	SAT0606-HPRâ€HOW DO THE PATIENTS THAT DECLINE TO PARTICIPATE IN A LIFESTYLE INTERVENTION STUDY DIFFER FROM THOSE WHO ACCEPT? A REGISTER-BASED CROSS-SECTIONAL STUDY Annals of the Rheumatic Diseases, 2020, 79, 1263.2-1263.	0.9	0
386	AB0194â€VITAMIN D TRAJECTORIES IN EARLY DIAGNOSED, AGGRESSIVELY TREATED RHEUMATOID ARTHRITIS PATIENTS: A 10 YEAR LONGITUDINAL COHORT STUDY BASED ON THE DANISH CIMESTRA TRIAL. Annals of the Rheumatic Diseases, 2020, 79, 1397-1397.	0.9	0
387	AB1243â€TRAINING AND VALIDATION OF A MULTIVARIATE PREDICTOR OF RISK OF RADIOGRAPHIC PROGRESSI FOR PATIENTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1913.1-1913.	ON 0.9	0
388	Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
389	Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial. Scandinavian Journal of Rheumatology, 0, , 1-11.	1.1	0